Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues have?

Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues has 216 citations in the OpenAlex counts ScholarIQ stores.

When was Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues published?

Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues has 2009 year in the ScholarIQ index.

What is the open-access status of Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues?

Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues has green oa status in the ScholarIQ index.

What is the DOI of Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues?

The DOI for Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues is on the source record.

What is the PMID of Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues?

The PMID for Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues is on the source record.

What is the OpenAlex record for Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues?

The OpenAlex for Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues is on the source record.